Monday, June 30, 2025 6/30/2025

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium.

Award Number: UM1OD023221
ORGANIZATION: OFFICE OF THE DIRECTOR, NIH
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/16/2011
PERIOD OF PERFORMANCE END DATE: 07/31/2027

Group Awards By:

View Award Description

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium. - KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium PROJECT SUMMARY/ABSTRACT This application will renew funding for our consortium (DTCC) to continue to participate in Phase3 of the NIH Knockout Mouse Phenotyping Project (KOMP2). DTCC proposes to produce 600 null mutant mouse lines for genes with little to no functional annotation or phenotype by electroporation of Cas9 RNA-guided nucleases into 1-cell stage C57BL/6N zygotes and upload all production data and information to the International Mouse Phenotyping Consortium (IMPC)’s GenTaR database. DTCC will then generate age-matched and sex-balanced cohorts of 600 mutant homozygous or heterozygous mouse lines and wildtype C57BL/6N control mice for juvenile phenotyping in the Early Adult Pipeline and embryo phenotyping of homozygous nonviable mouse lines in the Embryo Pipeline. We will use categorical and continuous tests and procedures standardized by the IMPC and selected by balancing the breadth of phenotyping with a >4% abnormal phenotype hit rate across the IMPC during KOMP-Phase2 to develop an informative multi-domain pipeline. After quality assurance of our processes and quality control of our products, all data, metadata, and images will be available for upload to the Data Coordination Center (DCC). After additional quality control at the DCC, our data will be transferred to the Central Data Archive for statistical analysis and from there to the IMPC web portal for public access. All mutant mouse lines will be available upon request by the research community as live mice while production and phenotyping are in progress and thereafter as frozen germplasm and as live mice after cryorecovery from the Mutant Mouse Resource and Research Center and Canadian Mouse Mutant Resource. Additional biological resources (e.g., fixed tissue) will also be available through the web portal and all DTCC’s standardized operating procedures, expertise, and advice are available by email or videoconference. To continuously adapt and improve high-throughput design, production, and phenotyping, DTCC will conduct technology development projects to increase efficiency of production (e.g., expanding the genome editing toolbox, generating landing- pad alleles) and pilot phenotyping tests (e.g., automated home-cage monitoring, whole-body MRI) to assess their utility, capability, cost-effectiveness, and informative value to the Early Adult and Embryo Pipelines. In addition to prioritizing genes with a human ortholog and no or little functional annotation, DTCC will also actively request the scientific community to nominate genes to produce and phenotype that have likely disease associations. Grant-funded member centers of DTCC include the University of California Davis (UCD; lead institution) and The Center for Phenogenomics (TCP; subcontractor) in Toronto, Canada. We propose to leverage our extensive experience and continue to use and refine well-tested coordinated management, strategy, protocols, and processes established in KOMP2-Phase1 and 2. In KOMP2-Phase2, DTCC is on track to complete all committed deliverables and complete all value-added expected activities (e.g., accelerated CRISPR/Cas9 electroporation of C57BL/6N zygotes, increased production rate of germline mutants, completion of both production and phenotyping pipelines, and finishing of technology development projects). In addition to input from NIH Program Officers, DTCC will be guided by advice and recommendations of local scientific domain experts and the IMPC Panel of Scientific Consultants. DTCC will participate in all KOMP2 and IMPC activities, including monthly videoconferences, extant and ad hoc committees, special interest workgroups and meetings, national and international conferences, and site visits. To maximize the scientific output and impact on biomedical research, DTCC also commits to coordinate its efforts with those production, phenotyping, and technology development efforts at other KOMP2-Phase3 funded centers. By the end of 5 years, DTCC will have contributed genotype-confirmed mouse lines and validated multi-body system phenotyping data for 600 mutant mouse lines on time and within budget to contribute to the global effort to functionally annotate the mammalian genome.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $2,365,000 )
2024	2024	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	13	7/18/2024	NON-COMPETING CONTINUATION	$2,365,000
2024	2023	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	12	4/10/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,365,000

Issue Date FY: 2023 ( Subtotal = $2,365,000 )
2023	2023	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	004	12	8/7/2023	NON-COMPETING CONTINUATION	$2,365,000
2023	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	002	11	3/10/2023	COMPETING CONTINUATION	$316,106
2023	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	003	11	3/18/2023	COMPETING CONTINUATION	$0
2023	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	10	3/10/2023	SUPPLEMENT FOR EXPANSION	-$296,291
2023	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	10	3/10/2023	SUPPLEMENT FOR EXPANSION	-$19,816
														Subtotal = $2,365,000

Issue Date FY: 2022 ( Subtotal = $2,725,667 )
2022	2022	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	11	8/12/2022	COMPETING CONTINUATION	$2,725,667
														Subtotal = $2,725,667

Issue Date FY: 2021 ( Subtotal = $2,551,619 )
2021	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	003	10	7/28/2021	SUPPLEMENT FOR EXPANSION	$159,953
2021	2021	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	002	10	7/21/2021	SUPPLEMENT FOR EXPANSION	$2,391,666
2021	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	10	7/19/2021	NON-COMPETING CONTINUATION	$0
2021	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	10	3/16/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,551,619

Issue Date FY: 2020 ( Subtotal = $6,129,573 )
2020	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	002	10	7/23/2020	NON-COMPETING CONTINUATION	$6,058,421
2020	2020	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Trans-NIH Research Support	001	9	4/7/2020	SUPPLEMENT FOR EXPANSION	$71,152
2020	2019	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	9	3/19/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $6,129,573

Issue Date FY: 2019 ( Subtotal = $6,658,702 )
2019	2019	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	002	9	7/23/2019	NON-COMPETING CONTINUATION	$6,058,702
2019	2019	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	003	9	8/22/2019	SUPPLEMENT FOR EXPANSION	$600,000
2019	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	8	3/19/2019	NON-COMPETING CONTINUATION	$0
2019	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	8	10/30/2018	SUPPLEMENT FOR EXPANSION	$0
														Subtotal = $6,658,702

Issue Date FY: 2018 ( Subtotal = $6,059,352 )
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	8	8/27/2018	SUPPLEMENT FOR EXPANSION	$199,305
2018	2018	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	8	8/1/2018	NON-COMPETING CONTINUATION	$5,860,047
														Subtotal = $6,059,352

Issue Date FY: 2017 ( Subtotal = $6,735,199 )
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	001	7	7/27/2017	NON-COMPETING CONTINUATION	$5,843,797
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	6	3/29/2017	SUPPLEMENT FOR EXPANSION	$131,465
2017	2017	UNIVERSITY OF CALIFORNIA, DAVIS	1850 RESEARCH PARK DR, STE 300	DAVIS	CA	95618	YOLO	USA	Trans-NIH Research Support	002	7	9/13/2017	SUPPLEMENT FOR EXPANSION	$759,937
														Subtotal = $6,735,199

Issue Date FY: 2016 ( Subtotal = $4,860,047 )
2016	2016	UNIVERSITY OF CALIFORNIA	1850 RESEARCH PARK DRIVE	DAVIS	CA	95618	YOLO	USA	Research Infrastructure Programs	000	6	9/8/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$4,860,047
														Subtotal = $4,860,047

Grand Total All Awards = $40,450,159

Top

All Categories

About

Search

Reports

Data Submission

Award Information

KOMP2-Phase3 Production and Phenotyping by the DTCC Consortium.

Award Number: UM1OD023221

ORGANIZATION: OFFICE OF THE DIRECTOR, NIH

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/16/2011

PERIOD OF PERFORMANCE END DATE: 07/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer